MVIR:STO
Medivir AB
1,47Â SEK
arrow_upward
+0,82%(+0,012) 1K
9-okt, 13:23:08 (GMT+2) · SEK
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoMVIR tikeri uchun statistika yaratilmoqda...
Ochish
1,47Â SEK
Yuqori
1,50Â SEK
Past
1,45Â SEK
Bozor kapitali
916,42Â mln
Oʻrtacha hajm
1,41Â mln
Hajmi
1,19Â mln
52 haftalik eng yuqori
2,88Â SEK
52 haftalik eng past
0,34Â SEK
Aksiya boʻyicha daromad
-0,37Â SEK
Muomaladagi aksiyalar
624,18Â mln
Xodimlar soni
6
Ochish
1,47Â SEK
Yuqori
1,50Â SEK
Past
1,45Â SEK
Bozor kapitali
916,42Â mln
Oʻrtacha hajm
1,41Â mln
Hajmi
1,19Â mln
52 haftalik eng yuqori
2,88Â SEK
52 haftalik eng past
0,34Â SEK
Aksiya boʻyicha daromad
-0,37Â SEK
Muomaladagi aksiyalar
624,18Â mln
Xodimlar soni
6
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Stock Titan
·
25 daqiqa oldin
15 new hires receive stock awards from Ocular Therapeutix
Yahoo Finance
·
1 soat oldin
History says midterms could hand the S&P 500 a year-end rally: Chart of the Day
MarketBeat
·
14 daqiqa oldin
New Era Energy & Digital (NASDAQ:NUAI) Upgraded at Roth Capital
Reuters
·
49 daqiqa oldin
Wall St futures gain as oil slips; telecoms pressured by SpaceX spectrum deal
Profil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Medivir AB haqida